Synaptogenix, Inc. (NASDAQ:SNPX) Sees Large Increase in Short Interest

Synaptogenix, Inc. (NASDAQ:SNPX) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 11,300 shares, a growth of 130.6% from the August 31st total of 4,900 shares. Based on an average daily volume of 37,300 shares, the short-interest ratio is currently 0.3 days. Approximately 0.9% of the company’s stock are short sold.

Synaptogenix Trading Down 5.4 %

Shares of SNPX stock traded down $0.17 during trading hours on Friday, hitting $2.97. The company had a trading volume of 8,864 shares, compared to its average volume of 39,917. The firm’s fifty day moving average is $3.59 and its 200 day moving average is $4.21. Synaptogenix has a 12 month low of $2.72 and a 12 month high of $11.47.

Synaptogenix (NASDAQ:SNPX) last announced its earnings results on Wednesday, August 14th. The company reported ($1.18) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Maxim Group upgraded Synaptogenix from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Thursday, July 11th.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.